2.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
TXMD Q3 2023 Earnings: A Significant EPS Miss Amid No Reported RevenueLow Growth Earnings - newsline.com
TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser
What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsBanking Earnings Report - The Legal Advocate
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
TXMD Reports Strong Q1 Revenue Growth and Explores Strategic Alt - GuruFocus
Is TherapeuticsMD (TXMD) 13.4% Overvalued After Q1 2026 Earnings - GuruFocus
[10-Q] TherapeuticsMD, Inc. Quarterly Earnings Report - Stock Titan
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks
TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com
TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
What TherapeuticsMD (TXMD) flagged as biggest challenges ahead | Q3 2023: EPS Misses ViewsStock Trading Network - Newser
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TXMD Should I Buy - Intellectia AI
TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD Financials: Income Statement, Balance Sheet & Cash Flow | Therapeuticsmd Inc - Stock Titan
TXMD (TherapeuticsMD) shares gain 5.8 percent despite wider than expected Q3 2023 per share loss.Earnings Revision Report - Newser
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):